机构：[1]Department of Pulmonary and Critical Care Medicine, Institute of Respiratory Disease, The First Hospital of China Medical University, Shenyang, China[2]Department of Geriatric Respiratory, The First Hospital of Kunming Medical University, Kunming, China.内科科室呼吸内科昆明医科大学附属第一医院老年呼吸病区干疗科内科科室
By evaluating S100 calcium binding protein A9 (S100A9) and Klebs von den Lungen-6 (KL-6) expression in patients with 4 common interstitial lung diseases (ILDs), we aimed to investigate whether S100A9 or KL-6 can be of any value in the differential diagnosis of these ILDs and simultaneously signal the disease progression. We collected the data of patients diagnosed with the 4 ILDs and underwent fiber-optic bronchoscopy and BAL in the First Affiliated Hospital, China Medical University from January 2012 to December 2020. The data related to BGA, C-reactive protein, pulmonary function test, total number and fraction of cells, T lymphocyte subsets in bronchoalveolar lavage fluid (BALF), and the expression of S100A9 and KL-6 in BALF and serum were collected. We analyzed, whether S100A9 or KL-6 could serve as a biomarker for differential diagnosis between the 4 common ILDs; whether the levels of S100A9 and KL-6 correlated with each other; whether they were correlated with other clinical parameters and disease severity. This study included 98 patients, 37 patients with idiopathic pulmonary fibrosis (IPF), 12 with hypersensitivity pneumonitis, 13 with connective tissue disease-associated ILD, and 36 with sarcoidosis (SAR): stage 1(18), stage 11(9), stage III (5), and stage IV (4). The expression of KL-6 in BALF was significantly higher in IPF patients than other 3 groups (all P-value < .05). However, there was no significant difference in the levels of S100A9 in BALF and serum between the 4 groups (P-value > .05). The levels of S100A9 in BALF of IPF patients was positively and significantly correlated with KL-6 expression and the percentage of neutrophils in BALF (P-value < .05). Along with the stage increase of SAR patients, the level of S100A9 in BALF gradually increased, which was negatively and significantly correlated with the forced vital capacity/predicted, carbon monoxide diffusing capacity/predicted%, and PaO2 (all P-value < .05). The expression of KL-6 in BALF can be used as a biomarker to differentiate IPF from the other 3 common ILDs. While, this was not the case with expression of S100A9 in BALF and serum. However, the expression S100A9 in BALF is useful to indicate the progression of SAR. Thus, simultaneous measurement of KL-6 and S100A9 levels in BALF makes more sense in differential diagnosing of the 4 common ILDS.
基金：
National Key Technology Research and Development Program of the 13th National 5-year Development Plan
(2016YFC1304103) and Liaoning Province Revitalization Liaoning Talents Plan Project (XLYC1805002).
第一作者机构：[1]Department of Pulmonary and Critical Care Medicine, Institute of Respiratory Disease, The First Hospital of China Medical University, Shenyang, China
通讯作者：
通讯机构：[1]Department of Pulmonary and Critical Care Medicine, Institute of Respiratory Disease, The First Hospital of China Medical University, Shenyang, China[*1]Department of Pulmonary and Critical Care Medicine, Institute of Respiratory Disease, The First Hospital of China Medical University, No. 155 Nanjing Street, North, Shenyang 110001, China
推荐引用方式(GB/T 7714)：
Lin Li,Zhao Yabin,Li Zhenhua,et al.Expression of S100A9 and KL-6 in common interstitial lung diseases[J].MEDICINE.2022,101(17):doi:10.1097/MD.0000000000029198.
APA：
Lin, Li,Zhao, Yabin,Li, Zhenhua,Li, Yun,Wang, Wei...&Wang, Qiuyue.(2022).Expression of S100A9 and KL-6 in common interstitial lung diseases.MEDICINE,101,(17)
MLA：
Lin, Li,et al."Expression of S100A9 and KL-6 in common interstitial lung diseases".MEDICINE 101..17(2022)
